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Background/aim: Pseudoangiomatous stromal hyperplasia (PASH) is a rare and benign mesenchymal proliferative breast lesion. Our
aim is to review the clinical and radiological features of PASH and define a standard approach for its diagnosis and management.
Materials and methods: Clinical records of 35 consecutive patients with PASH were retrospectively reviewed between 2009 and 2015.
Patients with clinically or radiologically detected mass and patients who underwent biopsy for other indications and were diagnosed
incidentally were included in the study.
Results: There were 34 female patients and one male patient with gynecomastia. Twenty-three patients had palpable masses, and 16
of them were diagnosed as PASH with a median size of 3.1 cm. PASH did not show any specific features in radiological imaging.
Core needle biopsy was performed for 3 patients before surgical excision; however, the lesions had not been diagnosed as PASH. In
pathological examination, lesions associated with PASH showed nonproliferative changes in 14 patients, proliferative changes without
atypia in 17, one phyllodes tumor, one in situ tumor, and one invasive cancer.
Conclusion: Imaging findings of PASH are nonspecific. It is difficult to give a true prognostic diagnosis through pathological evaluation
of big masses with core needle biopsy. We recommend surgical excision, especially for big lesions with suspicious features.
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1. Introduction
Pseudoangiomatous stromal hyperplasia (PASH) is a rare
and benign mesenchymal proliferative breast lesion. Its
clinical and radiological findings and optimal treatment
are still not clear. It was first described in 1986 by Vuitch
et al. (1) in nine patients having nodular mass lesions
with a histological pattern, which simulated, but did not
in fact constitute, a vasoformative proliferation. PASH is
often seen as a microscopic lesion detected incidentally
(2); sometimes as a clinically palpable mass or as multiple
nodular lesions; or, rarely, as a giant mass causing
asymmetry of the breasts (2–4). The clinical and radiologic
features of PASH often mislead to a prediagnosis of
fibroadenoma, phyllodes tumor, or hamartoma (5–9).
Initially thought to be a variant of breast hamartoma,
PASH is now accepted as a benign proliferation of stromal
myofibroblasts. The histologic appearance is characterized
by interanastomosing angulated and slit-like empty spaces,
lined by slender spindle cells and surrounded by dense
collagenous stroma. These slits lined by myofibroblasts
may be a fixation artifact caused by the retraction of the
collagenous stroma. Although there are no red blood cells
* Correspondence: biz.2006@hotmail.com
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in these spaces, i.e. they are not vascular spaces, PASH is
occasionally misdiagnosed as low-grade angiosarcoma
(10).
The aim of this study is to review the clinical and
radiological features of PASH by adding our institutional
experience with the purpose of helping define a standard
approach for the diagnosis and management of PASH.
2. Materials and methods
Following approval by the Institutional Review Board of
the Ankara Oncology Education and Research Hospital,
a pathology database search was compiled to identify
cases with a diagnosis of PASH from January 2009 to
September 2015. Over a 6-year period, 35 cases of PASH
were determined and the clinical records of the 35
consecutive patients who underwent excisional breast
biopsy, lumpectomy, or mastectomy at our hospital were
retrospectively reviewed. All patients with either palpable
or radiologically detected mass diagnosed as PASH, and
patients with PASH found incidentally in breast specimens
included in the study. All patients who were 40 years
old and above were examined both with mammography
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and sonography, whereas others were evaluated just with
sonography. Mammography was performed only in one
younger patient, who was 33 years old with a suspected
breast mass. Magnetic resonance imaging was performed
in 3 patients; one had multiple breast lesions with confusing
characteristics in other imaging modalities, and 2 patients
had inconclusive findings of a breast lesion on sonography.
All patients underwent surgical excision, except for two,
who had malignancy and underwent lumpectomy or
mastectomy with sentinel lymph node biopsy. Followup procedures included clinical breast examination,
breast sonography, and mammography, which were
recommended to all patients aged 40 years and above,
initially 6 months after surgery and then annually. For
patients younger than 40 years, follow-up was performed
with clinical breast examination and sonography 6 months
after surgery, then annually. Magnetic resonance imaging
was used in all patients when necessary.
Initially, all pathological specimens were examined
at the time of diagnosis by experienced pathologists at
the high-volume specialty breast center of our hospital’s
pathology department. Then, following approval by our
Institutional Review Board, microscopic slides of all cases
identified as PASH were re-reviewed by a single pathologist.
Immunohistochemical studies were performed on
formalin-fixed tissue from PASH cases containing cellular
areas using anti-CD34, anti-CD31, antidesmin, and
antismooth muscle antibodies as well as the iView DAB
detection kit (Ventana Medical Systems Inc., Tucson, AZ,
USA).
Age at diagnosis, sex, menopausal status, use of
hormone replacement therapy, personal and family history
of cancer, predominant physical examination findings,
radiological findings, presence of previous needle biopsy,
associated breast pathologies as benign nonproliferative
changes, benign proliferative changes without atypia,
benign proliferative changes with atypical hyperplasia
and malignant pathology with PASH, length of surgical
margins, and treatment modalities were noted. In the
follow-up period, patients were divided into 3 groups as
adjacent, 1–2 cm, and more than 2 cm, according to the
surgical margin width.
2.1. Statistical analyses
Data were descriptively summarized using frequencies
and percentages for categorical variables and medians for
continuous variables. The association of the recurrence rate
and the surgical margin width were compared using the
Fisher exact test or the Pearson chi-square test. The duration
of follow-up was defined as the time between the date of
the diagnosis of PASH to the last contact. P < 0.05 was
considered statistically significant. All analyses were carried
out using SPSS 21.0 (IBM Corp., Armonk, NY, USA).

3. Results
Approximately 12,000 breast biopsies were performed at
the Ankara Oncology Education and Research Hospital
between January 2009 and September 2015, and about
3000 of these biopsies were wire-localized by image
guidance. Nearly 4300 of all breast biopsies were malignant
and 35 were determined as PASH cases. Nineteen of 35
PASH diagnoses (54.3%) were incidental. All patients
were female except one; two out of 34 patients were
postmenopausal. Among nonincidental PASH patients,
there was only one postmenopausal woman, and 15
patients with nonincidental PASH were premenopausal.
Postmenopausal patients had not received hormone
replacement therapy. The male patient had gynecomastia.
None of the patients had a family history of breast cancer.
Median age of the enrolled female patients was 39 years
(range: 15–66 years) while the male patient was 27
years old. Figure 1 shows age distribution according to
nonincidental PASH.
Painless palpable breast mass was found in 23 patients
(65.7%) on physical examination. Other lesions were
detected by sonography and/or mammography. Lesions
diagnosed as PASH (i.e. 16 nonincidental PASH lesions)
were defined as round or oval, heterogeneous, hypoechoic
lesions with regular margins and without posterior
acoustic enhancement at sonography in 14 patients; as
round or oval heterogeneous, hypoechoic lesions with
lobulation in 1 patient; and a heterogeneous hypoechoic
lesion with irregular margins in 1 other patient. When
classified according to the American College of Radiology
Breast Imaging Reporting and Data System (BI-RADS),
these nonincidental, PASH-diagnosed lesions were BIRADS Category 4 in 14 patients due to mixed echotexture,
lobulation or irregular margins, and clinically growing
size. Conversely, 2 patients, one female with a giant mass of
8.5 cm and the single male patient with a 0.7-cm palpable
heterogeneous hypoechoic round lesion next to the
areola, were categorized as BI-RADS-3. Mammographic
examination was performed for 14 patients, and only in
3 of them was the PASH diagnosis not incidental. The
mammographic finding in these 3 nonincidental PASH
patients was a solid, well-circumscribed hyperdense
lesion. In the mammographic findings of incidentally
detected PASH, there was a mass with irregular shape
and spiculated margins in one patient and pleomorphic
microcalcifications in the other 2 patients. The remaining
patients had nonspecific mammographic findings.
Magnetic resonance imaging was performed in 3 patients,
and only in one of them was the PASH diagnosis not
incidental, with a circumscribed nodular mass hypointense
in T1-weighted images, hyperintense in T2-weighted
images, and revealing type 2 kinetics in the postcontrast
series.
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Figure 1. Nonincidental PASH presentation by age.

Twenty patients with palpable lesions underwent
surgical excision, and only 3 patients had core needle
biopsy before complete surgical excision. Diagnosis of
PASH was not possible with core needle biopsy in any of
these patients. Finally, all 23 palpable lesions were surgically
excised and 12 nonpalpable suspicious lesions were
removed by wire-localized, image-guided biopsy. Sixteen
of 23 palpable lesions (65.2%) were diagnosed as PASH in
final pathology, and the median size of these tumors was
3.1 cm (range: 0.7–8.5 cm). In these nonincidental PASH
patients, lesion size was greater in premenopausal women
than it was in postmenopausal ones, especially in the most
hormonally active ages (Figure 2). Other palpable lesions
associated with PASH were diagnosed as fibroadenoma in
2 patients, benign proliferative changes without atypia in 2
patients, low-grade phyllodes tumor in one patient, ductal
carcinoma in situ in one patient, and invasive carcinoma
in another patient. The patient with the in situ tumor was a
postmenopausal woman, whereas all others with palpable
lesions were premenopausal women or the male patient.
On pathological examination, 32 cases had typical
microscopic appearance for PASH. Lesions were composed
of anastomosing slit-like empty spaces lined with
spindle cells (Figure 3). In the other three cases, lesions
were cellular, and immunohistochemical studies were
performed for differential diagnosis. Lesions were CD34and SMA-positive while CD31 and desmin were negative.
In this series, other lesions associated with PASH were
benign nonproliferative changes in 14 patients and benign
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proliferative changes without atypia in 17 patients. In the
same breast, in addition to PASH, there was a concurrent
phyllodes tumor in one patient, ductal carcinoma in situ in
another patient, and invasive ductal carcinoma in a third
patient.
Follow-up data were available for 23 patients. The
median follow-up time was 35 months (range: 8–70
months). Among the followed patients, surgical margin
width was adjacent in 16 patients, 1–2 cm in 2 patients,
and more than 2 cm in 5 patients. During this period, none
of the patients had recurrence of PASH.
4. Discussion
PASH is a rare, benign proliferative breast lesion detected
mostly in premenopausal women. Its etiology and
pathogenesis remain unclear, but hormonal factors are
thought to play a role. In the literature, it was reported
that the stromal cells in PASH were progesterone receptorpositive (11) and that the histology of PASH resembles
that of intralobular stroma during the luteal phase of the
menstrual cycle (12). These findings support the hypothesis
that PASH is a hormone-dependent proliferation of
intralobular stromal cells (1,2,11). However, several
cases have been reported in postmenopausal women,
men, adolescents, and even in children (13). Our study,
having a majority of premenopausal patients (91%) and
a male patient with gynecomastia, seems to sustain this,
although there were two postmenopausal patients who
had not received hormone replacement therapy. Another
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Figure 2. Median size of nonincidental PASH lesion relative to patient age.

Figure 3. Anastomosing, slit-like spaces lined by spindle cells are seen in a dense
collagenous stroma (hematoxylin and eosin, original magnification 200×).

study in the literature supports the hormonal etiology of
PASH by reporting that the largest masses were seen in
premenopausal women, whereas the smallest were seen
in postmenopausal patients (10). Our study demonstrated
the same distribution pattern (Figure 2).
PASH cases are mostly identified as incidental
microscopic focus associated with various benign
nonproliferative and proliferative breast lesions. According
to Ibrahim et al. (2), it could be seen in as many as 23% of

all breast specimens. However, the nodular nonincidental
form determined by physical examination or imaging
modalities, i.e. by mammography or sonography, is less
frequent. Palpable nodules are usually firm, painless,
and mobile, without nipple or skin changes. Radiological
findings are nonspecific; a well-defined oval hypoechoic
nodular lesion resembling fibroadenoma is usually seen
in sonography. Hargaden et al. (5) described the imaging
characteristics of 149 cases of PASH on mammography
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and sonography. The most common presentations on
mammography were a circumscribed mass and, less
commonly, a focal asymmetric density. They found
no spiculated lesions, and asymmetric density and
microcalcifications were rare and unrelated to PASH. On
sonography, it was most commonly a well-circumscribed
hypoechoic or isoechoic oval mass with enhanced through
transmission. There are limited data in the literature on
magnetic resonance imaging. However, especially in the
mass-forming type of PASH, bright T2 slit-like spaces and
cystic components in the lesion favor PASH diagnosis.
Recent studies have described nonspecific magnetic
resonance findings, including variable signal intensity
in T1-weighted, T2-weighted, and contrast-enhanced
sequences usually with a type 1 (progressive) enhancement
curve (14). In our study, nonincidental PASH lesions
were mostly (14 of 16) benign-appearing round or
oval heterogeneous hypoechoic lesions in sonography,
which might have been considered as fibroadenomas
inadvertently.
In cases with suspicious features, surgical excision should
be considered, because PASH can coexist with a malignant
process and should not be accepted as a final diagnosis
on the basis of fine needle aspiration biopsy (FNAB) or
core needle biopsy alone. FNAB often produces acellular
specimens. If the cellularity is adequate, PASH does not
have any unique features on cytology and fibroadenoma,
phyllodes tumor, or fibrocystic changes should be ruled
out in differential diagnosis. The importance of FNAB is to
rule out malignant lesions rather than provide a definitive
diagnosis. On the other hand, core needle biopsy provides
more tissue than FNAB to diagnose PASH. Nevertheless,
a diagnosis with core biopsy may not be possible in every
case. Gresik et al., in their series of 80 patients, reported
that 65 patients had undergone core biopsy but only 65%
of the core biopsies ended with a diagnosis of PASH (9).
In our study, only 3 patients had core biopsy before total
surgical excision. Decisions for surgical excision of the
lesion without core needle biopsy seemed to be primarily
the surgeon’s preference, although it could be related to
the patient’s anxiety over a palpable lesion and to clinical
concerns such as enlarging size, as reported by Protos et al.
(15). In our series, none of the core biopsies were sufficient
for diagnosis of PASH. Instead, they were diagnosed as
suspicious for malignancy. If these lesions were followed
only with core biopsy, 2 cases of malignancy associated
with PASH could have been misdiagnosed.
On histologic examination, PASH shows a wide
spectrum of morphological changes, ranging from typical
appearance to more cellular spindle lesions. Cellular
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spindle lesions can be confused with other breast lesions,
especially phyllodes tumors or low-grade angiosarcomas.
Immunohistochemical staining with clinical and
radiologic findings can help to establish the diagnosis.
On immunohistochemistry the spindle cells are positive
for myofibroblastic markers such as CD34 and SMA but
are negative for endothelial markers such as CD31 and
von Willebrand factor antigen. PASH rarely presents as a
localized mass. More commonly it is an incidental finding,
coexistent with many benign and malignant breast lesions.
Previous studies have reported that up to 10% of specimens
had invasive carcinoma with PASH. If a diagnosis of PASH
is rendered on core biopsy, careful correlation of histologic
features with clinical and radiologic findings is required
to ensure that the target lesion has been appropriately and
adequately sampled. As a result, PASH in core biopsies has
pitfalls in diagnosis and may require complete excision
(16,17).
Criteria for total surgical excision include a size greater
than 2–3 cm, symptomatic tumors, or a diagnosis that is
questioned, such as with imaging findings of vascularity
or irregular margins. Additionally, an increase in size
documented by sonography or clinical examination raises
skepticism about the diagnosis and warrants removal of
the lesion (10,18,19). Moreover, in the literature there
is a PASH case with malignant transformation (20), and
some cases of PASH are reported to be in association with
concurrent malignancy, as in our series (21,22). Moreover,
there are some reports favoring follow-up of PASH lesions
after diagnosis with core needle biopsy (14,15), though
these authors pointed out that a palpable, symptomatic
mass with or without susceptible imaging findings should
be excised surgically.
In the literature, highly variable recurrence rates
are reported, ranging from 0% to 28.5%. Rates of lesion
growth were also reported as ranging from 0% to 71.4%
(1,23). In our study, all patients underwent complete
surgical excision. In the followed-up patients (23 of 35
patients, 65.7%), there was no recurrence or malignancy
occurrence in a median follow-up time of 35 months. It was
seen that surgical margin width did not affect recurrence
or malignancy occurrence.
Among all PASH cases, 45.7% were mass-forming
PASH with a median size of 3.1 cm, ranging from 0.7
to 8.5 cm. Their clinical and radiological features were
indistinguishable from other probable benign lesions.
When planning treatment and follow-up, it should be
considered that malignancy may accompany PASH and a
pathological evaluation by core needle biopsy may fail to
give a true diagnosis, especially in the mass-forming type.
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